These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

678 related items for PubMed ID: 28152315

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
    Resch B, Egger B, Kurath-Koller S, Urlesberger B.
    Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation.
    Turti TV, Baibarina EN, Degtiareva EA, Keshishyan ES, Lobzin YV, Namazova-Вaranova LS, Prodeus AP, Gudkov KM, Kruglova AI, Schulz GA, Notario GF.
    BMC Res Notes; 2012 Sep 04; 5():484. PubMed ID: 22943074
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants.
    DeVincenzo JP, Ambrose CS, Makari D, Weiner LB.
    Hum Vaccin Immunother; 2016 Apr 02; 12(4):971-5. PubMed ID: 26889568
    [Abstract] [Full Text] [Related]

  • 27. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.
    Checchia PA, Nalysnyk L, Fernandes AW, Mahadevia PJ, Xu Y, Fahrbach K, Welliver RC.
    Pediatr Crit Care Med; 2011 Sep 02; 12(5):580-8. PubMed ID: 21200358
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab.
    Manini MB, Matsunaga NY, Gianfrancesco L, Oliveira MS, Carvalho MRV, Ribeiro GLMT, Morais EO, Ribeiro MAGO, Morcillo AM, Ribeiro JD, Toro AADC.
    J Bras Pneumol; 2021 Sep 02; 47(5):e20210157. PubMed ID: 34669834
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee.
    Pediatrics; 2014 Aug 02; 134(2):e620-38. PubMed ID: 25070304
    [Abstract] [Full Text] [Related]

  • 33. One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America.
    Castillo LM, Bugarin G, Arias JC, Barajas Rangel JI, Serra ME, Vain N.
    J Pediatr (Rio J); 2017 Aug 02; 93(5):467-474. PubMed ID: 28236418
    [Abstract] [Full Text] [Related]

  • 34. Restrictive Palivizumab Use Does Not Lead to Increased Morbidity and Mortality in Pediatric Hematopoietic Stem Cell Transplantation Patients.
    Teusink-Cross A, Davies SM, Danziger-Isakov L, El-Bietar J, Grimley MS.
    Biol Blood Marrow Transplant; 2016 Oct 02; 22(10):1904-1906. PubMed ID: 27422147
    [Abstract] [Full Text] [Related]

  • 35. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep 02; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 36. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.
    Rajah B, Sánchez PJ, Garcia-Maurino C, Leber A, Ramilo O, Mejias A.
    J Pediatr; 2017 Feb 02; 181():183-188.e1. PubMed ID: 27855996
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD.
    Pediatr Infect Dis J; 2012 Jan 02; 31(1):e1-8. PubMed ID: 21960187
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.